Skip to Content
Merck
CN
  • A biocompatible "split luciferin" reaction and its application for non-invasive bioluminescent imaging of protease activity in living animals.

A biocompatible "split luciferin" reaction and its application for non-invasive bioluminescent imaging of protease activity in living animals.

Current protocols in chemical biology (2014-09-11)
Aurélien Godinat, Ghyslain Budin, Alma R Morales, Hyo Min Park, Laura E Sanman, Matthew Bogyo, Allen Yu, Andreas Stahl, Elena A Dubikovskaya
ABSTRACT

The great complexity of many human pathologies, such as cancer, diabetes, and neurodegenerative diseases, requires new tools for studies of biological processes on the whole organism level. The discovery of novel biocompatible reactions has tremendously advanced our understanding of basic biology; however, no efficient tools exist for real-time non-invasive imaging of many human proteases that play very important roles in multiple human disorders. We recently reported that the "split luciferin" biocompatible reaction represents a valuable tool for evaluation of protease activity directly in living animals using bioluminescence imaging (BLI). Since BLI is the most sensitive in vivo imaging modality known to date, this method can be widely applied for the evaluation of the activity of multiple proteases, as well as identification of their new peptide-specific substrates. In this unit, we describe several applications of this "split luciferin" reaction for quantification of protease activities in test tube assays and living animals.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lipopolysaccharides from Salmonella typhosa, γ-irradiated, BioXtra, suitable for cell culture